Answers are grounded in this paper and cite their sources.
Observational analysis shows securinine boosts CD8⁺ T cell activation in tumor models, indicating potential for immunotherapy.
Securinine (SEC) is a natural alkaloid isolated from Flueggea suffruticosa, which can suppress tumor growth of some types. T cells play a critical role in anti-tumor function. However, whether SEC mediates T cell-mediated anti-tumor effects remains unknown. Here, we found that SEC treatment suppressed tumor growth and improved survival in tumor-bearing mice in vivo. SEC promotes the percentage of IFN-γ⁺CD8⁺ T cell and TNF-α⁺CD8⁺ T cell in tumor microenvironments. SEC promoted T cell-mediated cytotoxicity in B16F10-OVA and OT-I co-culture systems. The anti-tumor function of SEC was abrogated after depleting CD8⁺ T cells in tumor-bearing mice. Mechanistically, SEC promoted T cell receptor (TCR) activation, increased IL-2 and IFN-γ production, and enhanced mitochondrial metabolism in CD8⁺ T cells. Additionally, SEC combination with anti-PD-1 suppressed tumor growth and improved survival in tumor-bearing mice. Thus, SEC enhances anti-tumor immunity by promoting CD8⁺ T cell activation, suggesting its potential role in tumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: